Identification of Two Hydrophobic Patches in the Active-Site Cavity of Human Carbonic Anhydrase II by Solution-Phase and Solid-State Studies and Their Use in the Development of Tight-Binding Inhibitors

Journal of Medicinal Chemistry
1994.0

Abstract

This paper describes inhibitors for human carbonic anhydrase II (HCAII, EC 4.2.1.1) that bind with nanomolar dissociation constants. These inhibitors were developed by exploiting interactions with hydrophobic "patches" in the lip of the active site of this enzyme. These patches are molecular surfaces presented by a phenylalanine on one face of the active-site cleft (Phe-131) and three adjacent hydrophobic residues on the opposite face (Leu-198 and Pro-201/202). Comparison of the affinities of molecules that can occupy either one or both of the two sites indicates that these hydrophobic interactions can contribute factors of 10(2)-10(3) to binding constants and that the strength of the interaction is relatively insensitive to the structure of the hydrophobic ligand. One of these inhibitors, the competitive inhibitor N-[N-[N-(4-sulfamoylbenzoyl)phenylglycyl]glycyl]glycine benzyl ester (17), has been studied by X-ray crystallographic methods in its complex with HCAII at 1.9-A resolution. The geometry of binding of the arylsulfonamide group of 17 is similar to geometries observed in other HCAII-arylsulfonamide complexes. The aromatic side chain of the phenylglycine residue of the inhibitor is inferred to pack against the hydrophobic Phe-131 face, and this interaction "steers" the peptide backbone of the inhibitor toward a region in the HCAII active site different from that occupied in the related triglycyl peptide. Attempts to design inhibitors capable of binding simultaneously to Phe-131 and Leu-198/Pro-201/202 did not lead to molecules that bound more tightly than those binding to these hydrophobic sites individually.

Knowledge Graph

Similar Paper

Identification of Two Hydrophobic Patches in the Active-Site Cavity of Human Carbonic Anhydrase II by Solution-Phase and Solid-State Studies and Their Use in the Development of Tight-Binding Inhibitors
Journal of Medicinal Chemistry 1994.0
Carbonic Anhydrase Inhibitors:  Stacking with Phe131 Determines Active Site Binding Region of Inhibitors As Exemplified by the X-ray Crystal Structure of a Membrane-Impermeant Antitumor Sulfonamide Complexed with Isozyme II
Journal of Medicinal Chemistry 2005.0
Carbonic Anhydrase Inhibitors with Dual-Tail Moieties To Match the Hydrophobic and Hydrophilic Halves of the Carbonic Anhydrase Active Site
Journal of Medicinal Chemistry 2015.0
Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a less utilized binding pocket than most hydrophobic inhibitors
Bioorganic & Medicinal Chemistry Letters 2010.0
Exploring structural properties of potent human carbonic anhydrase inhibitors bearing a 4-(cycloalkylamino-1-carbonyl)benzenesulfonamide moiety
European Journal of Medicinal Chemistry 2019.0
Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II ‘selective’ inhibitor celecoxib
Bioorganic & Medicinal Chemistry Letters 2006.0
Carbonic anhydrase inhibitors: Inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides—Solution and crystallographic studies
Bioorganic & Medicinal Chemistry Letters 2007.0
Carbonic anhydrase inhibitors: Design, synthesis, kinetic, docking and molecular dynamics analysis of novel glycine and phenylalanine sulfonamide derivatives
Bioorganic & Medicinal Chemistry 2015.0
Synthesis, Structure–Activity Relationship Studies, and X-ray Crystallographic Analysis of Arylsulfonamides as Potent Carbonic Anhydrase Inhibitors
Journal of Medicinal Chemistry 2012.0
Structural Basis for the Interaction Between Carbonic Anhydrase and 1,2,3,4-tetrahydroisoquinolin-2-ylsulfonamides
Journal of Medicinal Chemistry 2011.0